Table 3.

Effects on plasma glucose and plasma insulin following morning or evening dosing of vildagliptin 100 mg

		Active treatment period
	Placebo run-in (n = 40)	Morning dosing (n = 38)	Evening dosing (n = 38)	Least-squares mean difference between morning dosing and evening dosing (95% CI)	P value
Glucose (mg dl-1 h)
Total (AUE(0,24 h))	5540 ± 264	5136 ± 271	4870 ± 241	120 (−185, 425)	0.4296
Daytime (AUE(0,10.5 h))	2493 ± 113	2244 ± 121	2177 ± 114	6 (−136, 148)	0.9276
Night-time (AUE(10.5,24 h)	3132 ± 132	2891 ± 152	2693 ± 129	116 (−61, 293)	0.1918
Insulin (µU ml-1 h)
Total (AUE(0,24 h))	772 ± 52	747 ± 60	828 ± 69	−56 (−117, 5)	0.0707
Daytime (AUE(0,10.5 h))	403 ± 26	393 ± 33	421 ± 33	−18 (−52, 17)	0.3016
Night-time (AUE(10.5,24 h))	368 ± 27	354 ± 29	407 ± 36	−40 (−79, −0.1)	0.0495

Data are presented as mean ± SEM unless otherwise stated. AUE, area under the effect–time curve; CI, confidence interval.